Date of management change: October 14, 2017
Cambridge, MA-based Twentyeight-Seven-Therapeutics Appointed Kazumi Shiosaki as Chief Executive Officer
Twentyeight-Seven Therapeutics is a focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases.
Kazumi Shiosaki is Chief Executive Officer at Twentyeight-Seven Therapeutics. Previously, Kazumi held various senior HR leadership roles in the industry.
News
Short ProfileName: Kazumi Shiosaki
Title: Chief Executive Officer
Company: Twentyeight-Seven Therapeutics
Industry: Biotechnology
Current Contact InfoEmail: ***************@twentyeight-seven.com
Phone:.***.*03
To get full contact details, please sign in or
Other IT executives who recently changed jobs as well: Krivoruchka Mark, Torbett Russell, Eisner Robin, Knighton Dave, Scardelli Barbara, Ciullo Jean, Bates Barbara, Gentilozz Kathleen, Wei Juyuan, Rosenstein Richard, Maufort Brittany
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.
